Treatments Against Rheumatoid Arthritis and Effect on FDG PET-CT: TARGET
Brief description of study
This research study is being done to test the effect, safety, and tolerability of the experimental drug JBT-101 in subjects with systemic lupus erythematosus (SLE). We want to know if JBT-101 stops inflammation and how well JBT-101 is tolerated. The study will evaluate whether JBT-101 will decrease the pain associated with active arthritis or tendonitis. JBT-01 is not approved by the U.S. Food and Drug Administration (FDA) and can only be used in research studies. There are 6 study visits over 5 months. This study will compare JBT-101 to placebo which is a pill that doesn't have any drug in it. It is also double-blind means that both subjects and the researchers do not know whether a subject receives the study drug or a placebo. In case of an emergency, however, the study doctor can get this information.
Detailed description of study
Patients must have a diagnosis of Systemic Lupus Erythematosus and active joint arthritis in at least 2 joints. Patients are not eligible if they have aggressive and advancing organ disease, HIV or Hepatitis C, are taking daily doses of prednisone over 10mg for more than 30 days, use opiates chronically, or use recreational drugs.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Rheumatoid Arthritis,Synovitis,ra,arthritis,swelling,swollen joints,joint pain
-
Age: Between 45 Years - 99 Years
-
Gender: All
Updated on
05 Jul 2023.
Study ID: 828509
